Please assess the completion status of the following clinical trial:

Trial Title: Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly found isolated distal deep vein thrombosis~* Patients complicated with active cancer~* Patients who are scheduled to be treated by anticoagulation therapy.~Exclusion Criteria:~* Patients with anticoagulation therapy for the index event before 10 days of allocation.~* Patient under anticoagulation therapy for the purpose of other than the index event.~* Patients with thrombolysis therapy or IVC filter at the Index event.~* Patients with creatinine clearance less than 30 ml/min.~* Patients who are expected to have a life prognosis of 3 months or less.~* Patients with pulmonary embolism.~* Patients who are not appropriate for the participation of the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 12-month Edoxaban (Type: EXPERIMENTAL): Edoxaban for 12 months
- 3-month Edoxaban (Type: ACTIVE_COMPARATOR): Edoxaban for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).